59 reports

The drug candidate is a recombinant galectin-## protein.

  • Protein Therapy
  • Therapy
  • World
  • Product Initiative
  • Strykagen Corp.
  • RESOLVED BY THE EGM HAS BECOME EFFECTIVE.

THE DRUG CANDIDATE IS A PROTEIN AND CELLULAR BASED THERAPY BASED RECOMBINANT ADENO-ASSOCIATED VIRUS (RAAV) BIOLOGICAL NANOPARTICLE.

  • Blood Disease
  • Protein Therapy
  • Therapy
  • United States
  • Product Initiative

Of these proteins, albumin accounts for ##%, globulins for ##%, coagulation for ##% and other proteins for the remaining ##% share.

  • Blood Supply
  • Protein Therapy
  • World
  • Forecast
  • Grifols, S.A.

PLASMA PROTEIN THERAPIES ARE USED TO TREAT RARE AND CHRONIC DISEASES.

  • Blood Disease
  • Blood Supply
  • Healthcare
  • Hospital
  • Protein Therapy

The Company is developing OPRX-## to be the first ever oral protein treatment, as currently there are no other oral protein treatments available.

  • Protein Therapy
  • Brazil
  • United States
  • Company
  • Protalix BioTherapeutics, Inc.

HUMAN PROTEIN AND THE COMPANY WAS THE FIRST ONE TO MAKE VIRUS INACTIVE FACTOR VIII PRODUCT.

  • Protein Therapy
  • World
  • Baxter International Inc.
  • Biotest AG
  • CSL Limited

Grifols is one of the world top three producers of plasma-derived therapies.

  • Blood Disease
  • Clinical Trial
  • CT Scan
  • In Vitro Diagnostic Reagent
  • Protein Therapy

Additionally, we are screening patients in Australia for our Phase ## clinical trial of FPT##, our first-in-class CD## fusion protein.

  • Protein Therapy
  • United States
  • Company
  • Company Financials
  • Five Prime Therapeutics, Inc.

ACQUIRED THERAPY BUSINESS OF BIOTEST PHARMACEUTICALS CORPORATION, A ##% MINUS ONE SHARE OF ADMA.

  • Protein Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • ET-3I - DRUG PROFILE

DTX##, in Phase ## for the treatment of ornithine transcarbamylase (OTC) deficiency; DTX## in Phase ## for the treatment of GSDIa, and DTX## in Phase ## for the treatment of hemophilia A.

  • Blood Disease
  • Protein Therapy
  • United States
  • World
  • Product Initiative
  • BAYER HEALTHCARE: YOY REVENUE AND GROWTH RATE OF KOGENATE 2013-2015 ($ BILLIONS)
  • In March 2016, the company received US FDA approval for its recombinant hemophilia A drug, Kovaltry

Other mutations reduce the amount of protein but do not eliminate the protein' s activity, leading to mild or moderate hemophilia.

  • Protein Therapy
  • Baxalta Incorporated
  • Bayer AG
  • Biogen Idec Inc.
  • Grifols, S.A.

This results in the silencing of messenger RNA (mRNA) that codes for proteins and prevents the production of these disease-causing proteins.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • Biogen Idec Inc.

One case of nonserious rash and one case of myalgia were reported to be treatment-related.

  • Blood Disease
  • Protein Therapy
  • Therapy
  • Novo Nordisk Group
  • Pfizer Inc.

ACQUIRED THERAPY BUSINESS OF BIOTEST PHARMACEUTICALS CORPORATION, A ##% MINUS ONE SHARE OF ADMA.

  • Protein Therapy
  • Market Size
  • AbbVie Inc.
  • Pfizer Inc.
  • Sanofi S.A.

GRIFOLS IS ONE OF THE WORLD TOP THREE PRODUCERS OF PLASMA-DERIVED THERAPIES.

  • Clinical Trial
  • Hospital
  • Protein Therapy
  • Sealant
  • Therapy
  • ET-3 - DRUG PROFILE

No specific treatment was given for the anti-OBI-## antibodies.

  • Blood Disease
  • Medical Biotechnology
  • Protein Therapy
  • United States
  • Alnylam Pharmaceuticals, Inc.
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

The study is being conducted at the Cincinnati Children' s Hospital Medical Center, one of the NIAID-funded Vaccine and Treatment Evaluation Units (VTEUs).

  • Clinical Trial
  • Pharmaceutical
  • Protein Therapy
  • World
  • Product Initiative

MANF Therapeutics is the front-runner and primary worldwide intellectual property (IP) holder for MANF-based therapies including protein therapy, gene therapy and cell therapy.

  • Clinical Trial
  • Neurological Disorder
  • Protein Therapy
  • World
  • Neuren Pharmaceuticals Limited

Most of the adverse effects (AEs) were grade ## or ##.

  • Cancer
  • Medical Biotechnology
  • Monoclonal Antibody
  • Protein Therapy
  • Therapy

Arthritis Research Therapy; ##(##): ##-## Bridges D, et al. (2001).

  • Protein Therapy
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • Insys Therapeutics, Inc.

## ## ##. ## ## ##. ## GlaxoSmithKline Plc Samsung Bioepis Co Ltd South Korea ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## UCB SA ##. ## ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## ## ##. ## - ##. ## ## ## ##. ## ## - Biogen Inc United States ##. ## ##. ## ##. ## ##. ## ## ## ##. ## ## ##. ## Gilead Sciences Inc Corbus

  • Arthritis
  • Medical Biotechnology
  • Monoclonal Antibody
  • Pharmaceutical
  • Protein Therapy

The prominent features of this report are - ##.

  • Clinical Trial
  • Infectious Disease
  • Pharmaceutical
  • Protein Therapy
  • Tuberculosis
  • Orphan Dermatological Diseases, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type

Arthritis Research and Therapy. ##(##).

  • Dermatological Condition
  • Pathology
  • Protein Therapy
  • Therapy
  • Deals & Alliance

INTERLEUKIN ARE ONE OF SEVERAL PROTEINS IMPORTANT FOR LYMPHOCYTE PROLIFERATION.

  • Cardiovascular Disease
  • Hospital
  • Pharmaceutical
  • Protein Therapy
  • Therapy

Hoffmann-La Roche Ltd ## Jan 2010 ## Jun 2012 ## Jun 2012 ## ## ## ## Inosine Monophosphate Dehydrogenase (Inosinic Acid Dehydrogenase or IMP Oxidoreductase or IMPDH or EC ##. ##. ##. ##) Inhibitor Inosine Monophosphate Dehydrogenase (Inosinic Acid Dehydrogenase or IMP Oxidoreductase or IMPDH or

  • Clinical Trial
  • Lung Transplant
  • Protein Therapy
  • Therapy
  • Transplantation
  • WILL THEREAFTER BE ADVANCED INTO SCALE UP FOR CGMP PRODUCTION. THE PROJECT WILL UTILIZE CATALENT'S PROPRIETARY GPEX TECHNOLOGY.

THE DRUG CANDIDATE ACTS BY TARGETING MITOCHONDRIAL FISSION PROTEIN DYNAMIN-RELATED PROTEIN ## (DRP##).

  • Cell Therapy
  • Protein Therapy
  • Stroke
  • Therapy
  • Athersys, Inc.

IT IS A MODIFIED VERSION OF THE NATURAL PROTEIN ALPHA ## MICROGLOBULIN (A##M).

  • Genitourinary System Disease
  • Pathology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

Compared to the control group, CD##mAb treatment significantly decreased genes expression related to oxidative stress (sod-##, gpx-##, and txn), the inflammatory response (il-##, il-##, inf-g and tgf-b), as well as reduced protein levels of BAX, Caspase-##, MMP##, and M

  • Cardiovascular Disease
  • Medical Biotechnology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

Most of the adverse effects (AEs) were grade ## or ##.

  • Monoclonal Antibody
  • Protein Therapy
  • Therapy
  • United States
  • Product Initiative

In principle, protein therapy is similar to gene therapy, and involves protein delivery in specific amounts to the body to aid in precise functioning of different glands and other organs in the body.

  • Biopharmaceutical
  • Medical Biotechnology
  • Protein Therapy
  • Therapy
  • Market Size